Financings Of The Fortnight Looks To The High-Tech Sector For New Life-Science Capital Sources
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financings by Elcelyx, Jounce Therapeutics, Retrophin and e-Therapeutics.
You may also be interested in...
Hearing Therapy Pioneer Auris Medical Gets $50 Million Series C Financing
Auris Medical AG has completed Europe’s largest biotech investing round so far this year, led by Sofinnova Partners and Sofinnova Ventures, and hopes to advance the development of new otologic drugs for hearing dysfunction.
People Power: How The Crowd May Shape The Funding And Development Of Drugs
Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.
Elcelyx Forms Its Own Fund To Lead $20 Million Series C Financing
The money raised will bring the San Diego company’s total to $43 million and will be used to advance its delayed-release metformin, NewMet, through Phase IIb and into a partnership. The cash also will fund an efficacy trial for over-the-counter dietary supplement Lovidia.